ロード中...
Molecular signatures of chronic myeloid leukemia stem cells
BCR-ABL tyrosine kinase inhibitors (TKIs) are effective in controlling Philadelphia-positive (Ph(+)) chronic myeloid leukemia (CML) are unlikely to cure the disease because TKIs are unable to eradicate leukemia stem cells (LSCs) responsible for the disease relapse even after tyrosine kinase inhibiti...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4177606/ https://ncbi.nlm.nih.gov/pubmed/24252550 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2050-7771-1-21 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|